/NTBL
NTBL Stock - Notable Labs, Ltd.
Healthcare|BiotechnologyNASDAQ
$0.25-27.68%
$0.09 (-27.68%) • Oct 22
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.27
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NTBL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.25 – $0.25
TARGET (TP)$0.29
STOP LOSS$0.23
RISK/REWARD1:2.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-2.36
52W High$4.24
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $310,000 | $8,000 | $285,000 | $922,000 | $562,000 |
| Gross Profit | $113,000 | $-1,154,000 | $-1,336,000 | $-666,000 | $-879,000 |
| Gross Margin | 36.5% | -14425.0% | -468.8% | -72.2% | -156.4% |
| Operating Income | $-14,657,000 | $-12,924,000 | $-16,914,000 | $-24,483,000 | $-20,082,000 |
| Net Income | $-11,264,000 | $-14,407,000 | $-16,052,000 | $-24,225,000 | $-19,396,000 |
| Net Margin | -3633.5% | -180087.5% | -5632.3% | -2627.4% | -3451.2% |
| EPS | $-5.03 | $-6.50 | $-0.22 | $-0.48 | $-0.38 |
Company Overview
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish0 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 20th 2024 | JMP Securities | Downgrade | Market Perform | - |
Earnings History & Surprises
NTBLBeat Rate
50%
Last 12 quarters
Avg Surprise
-63.1%
EPS vs Estimate
Beats / Misses
6/6
Last 12 quarters
Latest EPS
$-0.48
Q4 2024
EPS Surprise History
Q4 22
+66.5%
$-1.64vs$-4.90
Q2 23
+99.4%
$-0.03vs$-5.25
Q3 23
+99.8%
$-0.01vs$-4.90
Q4 23
-17.1%
$-0.48vs$-0.41
Q1 24
-1169.8%
$-5.46vs$-0.43
Q2 24
-7.7%
$-0.42vs$-0.39
Q3 24
-27.9%
$-0.55vs$-0.43
Q4 24
+29.4%
$-0.48vs$-0.68
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 12, 2025 | — | — | — | — |
Q2 2025 | May 13, 2025 | — | — | — | — |
Q4 2024 | Nov 12, 2024 | $-0.68 | $-0.48 | +29.4% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.43 | $-0.55 | -27.9% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.39 | $-0.42 | -7.7% | ✗ MISS |
Q1 2024 | Mar 22, 2024 | $-0.43 | $-5.46 | -1169.8% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.41 | $-0.48 | -17.1% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-4.90 | $-0.01 | +99.8% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-5.25 | $-0.03 | +99.4% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $-4.90 | $-1.64 | +66.5% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-3.85 | $-4.13 | -7.4% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | $-3.67 | $-4.27 | -16.1% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-3.78 | $-0.13 | +96.4% | ✓ BEAT |
Q4 2021 | Dec 30, 2021 | — | $-0.13 | — | — |
Q3 2021 | Sep 29, 2021 | $-3.06 | $-0.09 | +97.0% | ✓ BEAT |
Q2 2021 | Jun 29, 2021 | — | $-0.12 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NTBL
What is NTBL's current stock price?
Notable Labs, Ltd. (NTBL) is currently trading at $0.25 per share. The stock has moved -27.68% today.
What is the analyst price target for NTBL?
No analyst price targets are currently available for this stock.
What sector is Notable Labs, Ltd. in?
Notable Labs, Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NTBL's market cap?
Notable Labs, Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does NTBL pay dividends?
No, Notable Labs, Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARAV
Aravive, Inc.
$0.04
Mkt Cap: $0.0B
ATNX
Athenex, Inc.
$0.20
Mkt Cap: $0.0B
BPTS
Biophytis S.A.
$8.22
Mkt Cap: $0.0B
EIGRQ
Eiger BioPharmaceuticals, Inc.
$8.50
Mkt Cap: $0.0B
FRES
Fresh2 Group Limited
$0.85
Mkt Cap: $0.0B
MTP
Midatech Pharma plc
$0.29
Mkt Cap: $0.0B
NOVN
Novan, Inc.
$0.09
Mkt Cap: $0.0B
PLXP
PLx Pharma Inc.
$0.09
Mkt Cap: $0.0B
PTN
Palatin Technologies, Inc.
$17.05
Mkt Cap: $0.4B
VBIV
VBI Vaccines Inc.
$0.07
Mkt Cap: $0.0B
Explore stocks similar to NTBL for comparison